Novo Nordisk ( NVO -1.22%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and ...

In its outlook for 2025, Novo Nordisk has predicted 'continued periodic supply constraints and related drug shortage ...

Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a ...

Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

Ozempic and Wegovy maker Novo Nordisk placed a print ad responding to the Super Bowl spot from competitor Hims & Hers.

Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. The ...

Shares of Novo Nordisk ( NVO -3.62%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but ...